Utilizing xenograft models, it was observed that fulvestrant fully inhibited BC cells with both wild-type ESR1, and with the E380Q mutation, whilst BC cells with Y537S mutations were less inhibited by fulvestrant therapy. This evidence concerns the gene ESR1 and breast cancer.